

REMARKS

Upon reviewing the claims once more, Applicants noted an unintentional error with respect to Claim 2. Claim 2 is dependent on Claim 1. Claim 1 recites a particular definition for Ring A i.e. "(C₃-C₈)-cycloalkanediyl or (C₃-C₈)-cycloalkenediyl". Pursuant to a restriction requirement, Applicants deleted the following words from the definition of Ring A i.e. "wherein one carbon atom of the (C₃-C₈)-cycloalkanediyl ring or the (C₃-C₈)-cycloalkenediyl ring may be replaced by an oxygen atom". See amendment of 3/30/07. The same words should have been deleted from Claim 2. The error was unintentional and done without any intent to mislead. Applicants respectfully request entry of this amendment after allowance.

Note that this amendment recites the changes (entered via the Examiner's amendment) that are described on page 3 of the Notice of Allowance. Those changes are noted as "previously presented" along with Applicants' previous amendments.

Respectfully submitted,



Barbara E. Kurys, Reg. No.: 34,650
Attorney/Agent for Applicant

sanofi-aventis Inc. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626

sanofi-aventis Docket No. DEAV2003/0081 US NP